Vimal Mehta - Mar 14, 2025 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Signature
/s/ Richard Steinhart, Attorney-in-Fact for Vimal Mehta, Ph.D.
Stock symbol
BTAI
Transactions as of
Mar 14, 2025
Transactions value $
$0
Form type
4
Date filed
3/17/2025, 06:35 PM
Previous filing
Jan 10, 2025
Next filing
Jun 16, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BTAI Common Stock Options Exercise +162 +4.35% 3.89K Mar 14, 2025 Direct F1
transaction BTAI Common Stock Options Exercise +217 +5.58% 4.1K Mar 15, 2025 Direct F1
holding BTAI Common Stock 125 Mar 14, 2025 BY SPOUSE
holding BTAI Common Stock 480K Mar 14, 2025 BY BIOXCEL LLC F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTAI Restricted Stock Units Options Exercise $0 -162 -12.42% $0.00 1.14K Mar 14, 2025 Common Stock 162 Direct F1, F3
transaction BTAI Restricted Stock Units Options Exercise $0 -217 -8.27% $0.00 2.41K Mar 15, 2025 Common Stock 217 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC and Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.
F3 On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
F4 On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.